Inhibitor Therapeutics, Inc. (INTI) Stock

About Inhibitor Therapeutics, Inc.

Inhibitor Therapeutics, Inc., established in 1992 and based in Tampa, Florida, is a pharmaceutical development enterprise. The company is dedicated to inventing and commercializing medical treatments for patients in the United States who suffer from various cancerous and non-cancerous cell proliferation conditions. A primary focus of their work involves advancing SUBA-Itraconazole, an oral variant of the drug itraconazole, for therapeutic applications in prostate and lung cancers. Furthermore, Inhibitor Therapeutics, Inc. has successfully completed a positive Phase 2b clinical trial for SUBA-Itraconazole in the management of basal cell carcinoma nevus syndrome. The organization was previously known as HedgePath Pharmaceuticals, Inc. until its name was officially changed in August 2019.

Inhibitor Therapeutics, Inc. is headquartered in US.

Inhibitor Therapeutics, Inc. (INTI) stock trades at $0.09 with a market capitalization of $15.01M. The stock is valued at a price-to-earnings (P/E) ratio of -4.48, price-to-book of -7.59, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.04 and $0.12, and currently trades 25.0% below its 52-week high.

On profitability, Inhibitor Therapeutics, Inc. generates a return on equity (ROE) of 525.87% — well above the market average, a sign of a high-quality business, return on capital employed of -328.03%, an operating margin of 0.00%, a net profit margin of 0.00%.

Official website: www.inhibitortx.com